Tesofensine

InChIKey
VCVWXKKWDOJNIT-ZOMKSWQUSA-N

SMILES
CCOC[C@H]1[C@H]2CC[C@H](N2C)C[C@@H]1C3=CC(=C(C=C3)Cl)Cl

• In advanced Parkinson disease, tesofensine caused more gastrointestinal adverse events than placebo, especially at higher dosages. (Archives of neurology, 2008)
• In advanced Parkinson disease, adding NS 2330 to levodopa did not appear to change dyskinesia severity compared with placebo. (Movement disorders, 2004)
• In early Parkinson disease, participants generally tolerated tesofensine well. (Movement disorders, 2007)
• In advanced Parkinson disease, tesofensine caused more neuropsychiatric adverse events than placebo, especially at higher dosages. (Archives of neurology, 2008)
• In advanced Parkinson disease, participants tolerated NS 2330 well. (Movement disorders, 2004)
• In early Parkinson disease, constipation was a commonly reported adverse event with tesofensine. (Movement disorders, 2007)
• In early Parkinson disease, insomnia was a commonly reported adverse event with tesofensine. (Movement disorders, 2007)
• In early Parkinson disease, dry mouth was a commonly reported adverse event with tesofensine. (Movement disorders, 2007)
• In early Parkinson disease, decreased body weight was common with tesofensine 1.0 mg. (Movement disorders, 2007)
• In early Parkinson disease, elevated heart rate was common with tesofensine 1.0 mg. (Movement disorders, 2007)
• In rats, acute tesofensine increased heart rate. (Obesity, 2013)
• In rodents, tesofensine caused few, if any, head-weaving movements at therapeutic doses, unlike phentermine. (PloS one, 2024)
• In rats, tesofensine caused head-weaving only in females, with less behavior than other dopamine-targeting drugs. (PloS one, 2025)
• In rats, acute tesofensine increased blood pressure. (Obesity, 2013)
• In rats, tesofensine was most often linked to abnormal mouth and tongue movements. (PloS one, 2025)

The doses that these studies used. They are not recommendations.